Abstract | OBJECTIVES:
Acute myeloid leukemia (AML) with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is an uncommon subtype of AML accounting for less than 0.5% of AML cases. AML with t(8;16)/KAT6A-CREBBP has characteristic clinical and pathologic features including disseminated intravascular coagulation ( DIC), leukemia cutis, hemophagocytosis, monocytic or myelomonocytic differentiation, is frequently associated with therapy-related AML and has a poor prognosis. We present a classic case of AML with t(8;16)/KAT6A-CREBBP occurring in a patient with both a germline NF1 mutation and recent cytotoxic therapy for embryonal rhabdomyosarcoma.
|
Authors | Liam Donnelly, Casey Rankins, Ximena Jordan Bruno, Wendy McKinnon, Katherine Devitt, Juli-Anne Gardner |
Journal | Journal of the Association of Genetic Technologists
(J Assoc Genet Technol)
Vol. 46
Issue 3
Pg. 135-139
( 2020)
ISSN: 1523-7834 [Print] United States |
PMID | 32889804
(Publication Type: Journal Article)
|
Copyright | Copyright© by the Association of Genetic Technologists. |